Table 3 The association between the immune cell position and clinicopathological characteristics.
From: Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent
Immune cell position (n = 131) | Univariate P-value | |||
|---|---|---|---|---|
Periductal (n = 54) n (%) | Touching (n = 47) n (%) | Intraductal (n = 30) n (%) | ||
Age at diagnosis (years) | 0.073 | |||
Median (range) | 60 (32–81) | 56 (27–73) | 53 (35–85) | |
Size (missing n = 17; cm) | 0.339 | |||
Median (range) | 3.00 (0.10–9.00) | 2.55 (0.1–9.20) | 3.00 (0.30–16.00) | |
Growth pattern | 0.081 | |||
Solid | 25 (46) | 34 (72) | 20 (67) | |
Cribriform | 22 (41) | 9 (19) | 6 (20) | |
Micropapillary | 7 (13) | 3 (6) | 4 (13) | |
Papillary | 0 (0) | 1 (2) | 0 (0) | |
Grade | 0.028 | |||
Low | 0 (0) | 1 (2) | 2 (7) | |
Intermediate | 5 (9) | 4 (9) | 8 (27) | |
High | 49 (91) | 42 (89) | 20 (67) | |
Calcification | 0.328 | |||
Absent | 9 (17) | 12 (26) | 9 (30) | |
Present | 45 (83) | 35 (74) | 21 (70) | |
Comedonecrosis | 0.087 | |||
Absent | 12 (22) | 18 (38) | 13 (43) | |
Present | 42 (78) | 29 (62) | 17 (57) | |
IHC DCIS subtype (missing n = 3) | 0.786 | |||
ER+PR±HER2− | 12 (23) | 9 (19) | 8 (28) | |
ER+PR±HER2+ | 13 (25) | 11 (23) | 10 (34) | |
ER−PR−HER2+ | 21 (40) | 22 (47) | 8 (28) | |
ER−PR−HER2− | 6 (12) | 5 (10) | 3 (10) | |
Ipsilateral recurence (missing n = 5) | 0.793 | |||
No | 50 (96) | 44 (96) | 26 (93) | |
Yes | 2 (4) | 2 (5) | 2 (7) | |
